Paul S. Rennie

University of British Columbia — Canada

Medicine · Health Sciences

64h-index13.6kcitations394works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(197), Estrogen and related hormone effects(100), Hormonal and reproductive studies(75), Virus-based gene therapy research(38), Cancer, Lipids, and Metabolism(32)

Publications394 total

Endoplasmic reticulum stress-driven nucleotide catabolism fuels prostate cancer
Cancer Letters·2025· 1 citedOpen Access
Retraction: AR-v7 protein expression is regulated by protein kinase and phosphatase
Oncotarget·2025Open Access
Author Correction: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
Nature Communications·2024Open Access
Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer
Scientific Reports·2024· 4 citedOpen Access
Supplementary Figure 4 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Table S1 and Figure S1-S4 from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
Supplementary Data from Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells
2023Open Access
Supplementary Figure 1 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Data from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
Supplementary Data from Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells
2023Open Access
Supplementary Figure 6 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 2 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Data from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 3 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 5 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 3 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 6 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 5 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Martin Gleave(17), Ladan Fazli(11), Colleen C. Nelson(11), Artem Cherkasov(11), Nicholas Bruchovsky(10), Helen Cheng(9), Eric Leblanc(8), Ian G. Mills(5), Fuqiang Ban(5), Robert J. Matusik(4), Nathan A. Lack(4), Emma S. Tomlinson Guns(4), Michael Cox(4), S. Larry Goldenberg(3), Lorne D. Sullivan(3), Robert Snoek(3), Eliana Beraldi(3), Fahri Saatcioglu(3), Kriti Singh(3), Peter Axerio-Cilies(3)